Overview

A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

Status:
Completed
Trial end date:
2012-09-05
Target enrollment:
Participant gender:
Summary
This study is intended to provide access to Romidepsin for participants who received Romidepsin in other trials sponsored by Gloucester Pharmaceuticals or Celgene Corporation and for participants whom the investigator feels may benefit from continuing treatment with Romidepsin.
Phase:
Phase 2
Details
Lead Sponsor:
Celgene
Celgene Corporation
Collaborator:
Celgene Corporation
Treatments:
Romidepsin